




# BASIC SCIENCE HEMATOLOGY THALASSEMIA


R2. SUPAKORN, MD  
SUPERVISOR A. NAWACHAI

# THALASSEMIA

- Inherited hemoglobin disorders, autosomal recessive
- Defective  $\alpha$ - or  $\beta$  – globin chain synthesis
- Impaired erythropoiesis, anemia and hypoxia
- Various of clinical phenotypes with marked difference in symptom severity and treatment requirements





# EPIDERMIOLOGY



- High incidence in Asia, Southeast Asia, Africa, Mediterranean
- In Thai, Thalassemia disease 1 % of population<sup>1</sup>
- Thalassemia carrier<sup>2</sup> :
  - $\alpha$ - Thalassemia carrier 20 -30
  - $\beta$  – thalassemia carrier 3-9%
- Hemoglobinopathy : HbE 13% [ South east 30 -50%], Hb constant spring (HbCS) 1-8%

1. Panich V, Pornpatkul M, Sriroongrueng W. The problem of thalassemia in Thailand. Southeast Asian J Trop Med Public Health. 1992; 23(Suppl 2): 1-6.

2. Fucharoen S, Winichagoon P, Thonglairuam V. Beta-thalassemia associated with alpha-thalassemia in Thailand. Hemoglobin. 1988; 12(5-6): 581-92.




$\alpha_2\beta_2 = \text{HbA}$



$\alpha_2\delta_2 = \text{HbA}_2$



$\alpha_2\gamma_2 = \text{HbF}$



Embryonic period	Fetal period	Adult period
Hb Gower-1 $\zeta_2\epsilon_2$	Hb F $\alpha_2\gamma_2$	Hb A $\alpha_2\beta_2$ 97%
Hb Gower-2 $\alpha_2\epsilon_2$	Hb A $\alpha_2\beta_2$	Hb A2 $\alpha_2\delta_2$ 2.5%
Hb Portland $\zeta_2\gamma_2$		Hb F <1%


# TYPE OF THALASSEMIA

## $\alpha$ Thalassemia

- 2 alpha globin genes encode on globin chain located on chromosome 16
  - Deletion and non-deletion
  - Type : 1. carrier ( $\alpha\alpha/\alpha-$ )
2. Thalassemia trait
- $\alpha$  thal-2 trait ( $-\alpha/\alpha\alpha$ )
  - $\alpha$  thal-1 trait ( $--/\alpha\alpha$ )
3. Disease
- HbH disease ( $--/-\alpha$ )
  - Bart's hydrop fetalis syndrome ( $--/---$ )

## $\beta$ Thalassemia

- Beta globin gene located on chromosome 11
- Point mutation
- 2 type : 1. Beta thalassemia carrier ( $\beta^+/\beta$ ,  $\beta^0/\beta^0$ ,  $\beta^+/\beta^+$ )
- 2. Beta thalassemia disease ( $\beta^0/\beta^0$ ,  $\beta^+/\beta^0$ ,  $\beta^0/\beta^E$ )



# Alpha thalassemia

After GA 6 -8 week : Zeta globin not produce amino acid

**\*\*\* Large deletion \*\*\***

Defect all  $\alpha_1$  and  $\alpha_2$  – globin from parental : Hb Bart's hydrop fetalis

Defect  $\alpha_1$  and  $\alpha_2$  – globin from parental : HbH disease ( $--/- \alpha$ )

Defect  $\alpha_2$  – globin from parental :  
Homozygous  $\alpha^+$  - thalassemia ( $-\alpha/-\alpha$ )



Defect  $\alpha_1$  – globin only :  
Heterozygous  $\alpha^0$  – thalassemia or  $\alpha$  thalassemia 1 trait ( $--/ \alpha\alpha$ )

Defect  $\alpha_2$  – globin :  $\alpha^+$  - thalassemia or silent  $\alpha$  thalassemia or  $\alpha$  thalassemia 2 trait or ( $-\alpha/ \alpha\alpha$ )


# Alpha thalassemia

is commonly caused by  
**large deletion**

## “Thalassemia effect”



# “ Hb variant ”



Abnormal mRNA translocation of termination codon mutation : Stop codon (at location 142 of  $\alpha_2$  - globin ) :

1.Hb constant spring (Hb CS) : TAA  $\rightarrow$  CAA ( produce glutamine )

2.Hb Pakse (Hb PS) : TAA  $\rightarrow$  TAT ( produce tyrosine)

$\rightarrow$  Hb Quong ze (Hb QS) : abnormal  $\alpha$  – globin stability of codon 125 (in exon2) : CTG  $\rightarrow$  CCG (Leucine  $\rightarrow$  proline)








# Beta thalassemia

$\beta^0$  = ไม่สร้าง  $\beta$  - globin เลย

$\beta^+$  = สร้าง  $\beta$ - globin ได้แต่ปริมาณลดลง

\*\*\* common point mutation \*\*\*


	$(\beta^0/\beta)$	$\beta$ -thalassemia trait
	$(\beta^0/\beta^0)$	Homozygous $\beta$ -thalassemia
	$(\beta^E/\beta)$	HbE trait
	$(\beta^E/\beta^E)$	Homozygous HbE
	$(\beta^0/\beta^E)$	$\beta$ -thalassemia / HbE disease

“Thalassemia effect”

“Hb variant”



Chromosome 11p 15.4



**Hb Tak**

- mutation in stop codon of  $\beta$ -gene
- elongated  $\beta$ -globin causing **high oxygen affinity**
- can cause 2° erythrocytosis

# Beta thalassemia

ลักษณะและตำแหน่งของการกลายพันธุ์	ความรุนแรง	ตัวอย่างที่พบได้
Point mutations		
Transcription		
Promoter region	$\beta^+$	nt-28(A>G), nt-87(C>A)
Cap site	$\beta^+$	nt+1 (A>C)
mRNA processing		
Splice junction	$\beta^0$	IVS-I-1 (G>T)
Splice site	$\beta^0$ or $\beta^+$	IVS-I-5 (G>C)
mRNA translation		
Initiation codon	$\beta^0$	ATG>ATA
Nonsense codon	$\beta^0$	codon 35 (C>A), codon 17 (A>T)
Frameshift	$\beta^0$	codon 41/42 (-TCTT)
Deletions		
Large deletion	$\beta^0$	619 bp deletion, 3.4 kb deletion

# Hb typing : normal


A









A<sub>2</sub>



F



# Hb typing



# Alpha thalassemia

	Genotype	Phenotype	Hbtyping
Hb Bart's hydrops	(--/--)	Dead	Hb Bart's > 80%
HbH disease	(--/- $\alpha$ )	Moderate anemia MCV $67 \pm 7$ fL	A <sub>2</sub> A Bart's H, AA <sub>2</sub> H H 5-50%, Bart's 3-4%
HbH c CS disease	(--/ $\alpha^{CS}\alpha$ )	Moderate anemia MCV $77 \pm 5$ fL	A <sub>2</sub> ABart'sHCS CS 2-5%, H 5-50%, Bart's 3-4%
Homozygous HbCS	( $\alpha^{CS}\alpha/\alpha^{CS}\alpha$ )	Mild-moderate anemia MCV $86 \pm 6$ fL	A <sub>2</sub> ABart's/A <sub>2</sub> ACS CS ~ 5%
Hb CS trait	( $\alpha^{CS}\alpha/\alpha\alpha$ )	$\pm$ decrease MCV	A <sub>2</sub> ACS
$\alpha$ - thal 1 trait	(--/ $\alpha\alpha$ )	$\pm$ mild anemia MCV $70 \pm 8$ fL	A <sub>2</sub> A : A <sub>2</sub> < 3.5 %
$\alpha$ - thal 2 trait	(-/ $\alpha\alpha$ )	Normal MCV	A <sub>2</sub> A : A <sub>2</sub> < 3.5 %


# Beta thalassemia

	Genotype	Phenotype	Hbtyping
Homozygous $\beta$ -thalassemia disease	$(\beta^0/\beta^0)$	Severe anemia MCV 57 -75 fL	$A_2F$
$\beta$ -thal/ HbE disease	$(\beta^0/\beta^E)$ or $(\beta^+/\beta^E)$	Moderate to severe anemia MCV $67 \pm 7$ fL	EF (E40-60%)
Homozygous HbE	$(\beta^E/\beta^E)$	Mild anemia MCV $73 \pm 6$ fL	E; E 80-100%
$\beta$ -thal trait	$(\beta^0/\beta)$ or $(\beta^+/\beta)$	$\pm$ mild anemia MCV $68 \pm 7$ fL	$A_2A$ ; $A_2 > 3.5\%$
Hb E trait	$(\beta^E/\beta^0)$	No anemia MCV $68 \pm 7$ fL	AE; E 25-35%

# Alpha and Beta thalassemia

	Genotype	Phenotype	Hbtyping
HbAEBart's disease	$(--/-\alpha)(\beta^E/\beta^0)$	Hb 7 -8.5 g/dL MCV $66 \pm 6$ fL	AEBart's E 13-17%
HbAEBart's with CS	$(--/\alpha^{CS}\alpha)(\beta^E/\beta)$	Moderate anemia Decrease MCV	AEBart's CS
HbEFBart's disease	$(--/-\alpha)(\beta^E/\beta^E)$ $(--/-\alpha)(\beta^0/\beta^E)$	moderate anemia Decrease MCV	EFBart's
HbE trait with $\alpha$ -thal trait	$(--/\alpha\alpha)(\beta^E/\beta)$ $(-\alpha/\alpha\alpha)(\beta^E/\beta)$	no anemia Decrease MCV	AE : E < 25%

# PATHOPHYSIOLOGY





# Clinical presentation

## General features

- Pallor
- Fatigue
- Dyspnea on exertion
- Poor appetite
- Palpitation
- Poor growth

## Feature of hemolysis

- Jaundice
- Gallstones
- Hyperuricemia (Gout)

**\*\* Beta thalassemia major symptoms occur when infant at age 6 -24 months**


## Excessive erythropoiesis

- Bone marrow expansion and bone disease : Thalassemia facies (prominent maxilla, Frontal bossing, malocclusion of teeth )
- Hepatomegaly
- Splenomegaly/hypersplenism
- Other extramedullary hematopoiesis :
  - Vertebral expansion
  - Medullary expansion
- Hypercoagulable state and vascular disease
  - Deep vein thrombosis
  - Pulmonary embolism
- Iron overload

# Laboratory

## Screening test

- CBC : MCV (< 80 fL), MCH (<27 pg)
- PBS – hypochromia, microcytic , target cell
- One tube osmotic fragility test (OFT) : 0.36% NaCl (hypotonic)
- DCIP precipitation test
- Hb E screen (microcolumn chromatography)




## \*\*CONFIRMATION TEST\*\*


### Hb typing

- Cellulose acetate
- Isoelectric focusing electrophoresis (IEF)
- High performance liquid chromatography (HPLC)

### DNA analysis or PCR ((polymerase chain reaction))



# Hb typing




## 1. High performance liquid chromatography (HPLC)



- Standard procedure for the initial evaluation of hemoglobin variants and thalassemia
- Rapid, automated
- Reliable quantitative measurements of hemoglobin A2 and F
- The chromatograms is analyzed by a microcomputer

## 2. Capillary electrophoresis (CE) detect

- $\beta$ -thalassemia trait : HbA2 >3.5%
- Hemoglobinopathies : Hb E trait, homozygous Hb E, Hb CS trait, homozygous Hb CS etc.
- Thalassemia disease : Hb H disease,  $\beta$ -thalassemia /Hb E



# Hb typing



**3. Isoelectric focusing electrophoresis (IEF) :** separation of amphoteric analytes according to their isoelectric point by the application of an electric field along a pH gradient formed in a capillary

**Gap PCR for**

- $\alpha$  - thal 1 SEA ( $--_{SEA}$ ) and THAI ( $--_{THAI}$ ) deletion
- $\alpha$  - thal 2 3.7 kb ( $-\alpha^{3.7}$ ) and 4.2 kb ( $-\alpha^{4.2}$ ) deletion

# Spectrum of disease

## Non-transfusion-dependent thalassemias

Transfusions  
seldom  
required

Occasional  
transfusions  
required

Intermittent  
transfusions  
required

Regular, lifelong  
transfusions  
required

$\alpha$ -thalassemia trait  
 $\beta$ -thalassemia minor  
HbC/ $\beta$ -thalassemia

Mild HbE/ $\beta$ -thalassemia  
HbH disease

Deletional HbH  
Moderate HbE/ $\beta$ -thalassemia


**Non-deletional HbH**  
 **$\beta$ -thalassemia major**  
**Severe HbE/ $\beta$ -thalassemia**

**Thalassemia intermedia**

Transfusion Dependent Thalassemia

# Management

- Hematopoietic stem cell transplant
  - Indication : transfusion dependent thalassemia
- Transfusion
  - occasional transfusion
  - regular transfusion – transfusion dependent (2-6 wks interval), keep pretransfusion Hb 9.0 -10.5 g/dL (but < 14 g/dL )
- Splenectomy
- Treatment of complication
  - Iron – mediated
  - Non iron – mediated
- Manipulation of HbF
- Gene therapy : use of autologous modified stem cells for engraftment



# Transfusion

- To improve the anemia and increase quality of life
- To suppress the ineffective erythropoiesis

## Indication for regular transfusion (Age < 18 years )


- Hb < 7 g/dL, 2 consecutive time, **without** current infection
- Hb > 7 g/dL with
  - facial bone change, Growth retardation (< P10), bone fracture, Extramedullary hematopoiesis : marked hepatosplenomegaly (> 5cm)

## Transfusion- dependent

- Severe anemia (Hb < 7 g/dL)
- Hepatosplenomegaly
- Extramedullary hematopoiesis
- Growth failure
- Genotype :
  - $\beta^0/\beta^0$ ,  $\beta^0/\beta^E$ , -- SEA/--SEA
  - some  $\beta^0/\beta^+$ , --SEA/ $\alpha^{cs}\alpha$
- Regular transfusion and iron chelation
- Hematopoietic stem cell transplantation (HSCT)
- Experimental gene therapy

## Non- Transfusion dependent

- Mild to moderate anemia (Hb 7-10 g/dL)
- Mild hepatosplenomegaly
- Genotype :
  - $\beta^+/\beta^+$ ,  $\beta^+/\beta^E$ , -- SEA/- $\alpha$
  - some  $\beta^0/\beta^+$ ,  $\beta^0/\beta^E$ , -- SEA/ $\alpha^{cs}\alpha$
- Occasional transfusion (infection or fever, pregnancy)



# Complication

- **Iron overload** : cardiac ( myocardial dysfunction, arrhythmia), Hepatic (cirrhosis), Endocrine (DM)
- **Cardiac complication** : CHF, Arrhythmia, pericarditis
- **Infection**
- **Endocrine abnormalities** : DM, growth deficiency, Delayed puberty & hypogonadism, hypothyroidism, hypoparathyroidism
- **Hypersplenism**
- **Thrombotic complication** : Pulmonary thromboembolism, Pulmonary hypertension, CVD
- **Gall stone**
- **Chronic leg ulcer**
- **Autoimmune/alloimmune hemolytic anemia**



# Chelation therapy

- **Monitor** : CBC, BUN/Cr, serum ferritin, UA (proteinuria), LFT
- **\*\* ear and eye examination** : Before and the q 1 year

## Indication in transfusion dependent

1. serum ferritin > 1000 mg/ml, 2 consecutive times within 1 -3 months
2. Regular transfusion > 1 year
3. Blood transfusion > 10 times
4. LIC in MRI T2\* >7 mg/kg (dry weight liver)
5. Cardiac MRI T2\* < 20 milliseconds

## Indication in Non - transfusion dependent


- Age > 10 yr in NTDT with
- serum ferritin > 800 ng/ml, 2 consecutive times within 1 -3 mo
- LIC in MRI T2\* > 5 mg/kg (dry weight liver )

## Chelation therapy

Property	DFO (Desferal)	Deferipone (GPO-L-ONE)	Deferasirox (Exjade)
Age	≥ 2 years old	≥ 6 years old	≥ 2 years old
Chelator: iron	1:1	3:1	2:1
Route of administration	Subcutaneous or intravenous	Oral tablet/ solution	Tablet oral suspension
Schedule	Administered over 8-24 hours, 5-7 days/wk	3 times a day	Daily + water 8 oz AC 30 min.
Usual dose	20-40 mg/kg/day	75-100 mg/kg/day	20-40 mg/kg/day
Half-life	20-30 minutes	3-4 hours	12-16 hours
Excretion	Urinary, fecal	Urinary	Fecal
Disadvantages	Local reaction Ear, eye toxicity Growth retardation and skeletal changes	GI disturbances, Transaminitis, Agranulocytosis 1%, Arthralgia, Low plasma zinc	GI disturbances, Transaminitis, GI bleeding, Rise in serum creatinine, Proteinuria, rash

# Prevention of thalassemia

แผนภูมิที่ 2.1 ขั้นตอนการตรวจวินิจฉัยทารกในครรภ์ก่อนคลอดที่เสี่ยงต่อ Hb Bart's hydrops fetalis



## Screening for couples at risk and genetic counselling

- Hb Bart's hydrop fetalis (--/--)
- Homozygous  $\beta$ -thalassemia ( $\beta^0/\beta^0$ )
- $\beta$ -thalassemia/ Hb E disease ( $\beta^0/\beta^E$ )


## Prenatal diagnosis

- Preimplantation genetic diagnosis (in vitro fertilization)
- Amniocentesis
- Chorionic villi sampling
- Umbilical cord blood sampling

# QUIZ

## Hb typing report form

- Hb 9.4%
- Hct 31.2 %
- MCV 52.3 fl
- MCH 15.7 pg
- RDW 22.5 %



Interpretation :  $\beta$ - thalassemia trait with or without  $\alpha$  thalassemia

# TAKE HOME MESSAGES

- $\alpha$  thalassemia : Large deletion VS  $\beta$  thalassemia : Point mutation
- $\alpha$  thalassemia : - carrier ( $\alpha\alpha/\alpha-$ )
  - > trait :  $\alpha$  thal-2 trait ( $-\alpha/\alpha\alpha$ ) and  $\alpha$  thal-1 trait ( $--/\alpha\alpha$ )
  - Disease : HbH disease ( $--/-\alpha$ ), Bart's hydrop fetalis syndrome ( $--/--$ )
- Beta thalassemia - carrier ( $\beta^+/\beta$ ,  $\beta^0/\beta^0$ ,  $\beta^+/\beta^+$ )
  - > Disease ( $\beta^0/\beta^0$ ,  $\beta^+/\beta^0$ ,  $\beta^0/\beta^E$ )
  - **Confirmation test : Hb typing ( CE, IEF, HPLC ), DNA analysis/ PCR**
  - regular transfusion – transfusion dependent [2-6 wks interval], keep pretransfusion Hb 9.0 -10.5 g/dL (but < 14 g/dL )
  - complication especially Iron overload
  - Indication for chelation : NTDT, TDT
  - Prenatal screening : Hb Bart's hydrop fetalis ( $--/--$ ), Homozygous  $\beta$ -thalassemia ( $\beta^0/\beta^0$ ),  $\beta$ - thalassemia/ Hb E disease ( $\beta^0/\beta^E$ )

THANK YOU